Overview

* Applied Therapeutics ( APLT ) Q3 net loss of $19 mln beats analyst expectations

* Company's Q3 operating income also beats analyst expectations

* Research and development expenses decreased by $5.2 mln compared to Q3 2024

Outlook

* Company to meet FDA in 4Q 2025 on govorestat for Classic Galactosemia

* Company plans further FDA meeting for Phase 3 trial design of govorestat in CMT-SORD

* New data supports continued govorestat development for PMM2-CDG

Result Drivers

* R&D - The decrease of approximately $5.2 million was primarily related to a decrease in clinical and preclinical expenses, stock-based compensation, regulatory and other expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.13

Q3 Net Beat -$18.99 -$23.30

Income mln mln (4

Analysts

)

Q3 Beat -$16.76 -$23.88

Operatin mln mln (4

g Income Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Applied Therapeutics Inc ( APLT ) is $2.50, about 63.6% above its November 12 closing price of $0.91

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)